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Abstract
Anaphylaxis is a source of anxiety for patients and healthcare providers. It is a medical emergency that presents with a broad
arrayof symptoms and signs, manyof which can be deceptively similar to other diseases such as myocardial infarction, asthma,
or panic attacks. In addition to these diagnostic challenges, anaphylaxis presents management difﬁculties due to rapid onset
and progression, lack of appropriate self-treatment education and implementation by patients, severity of the allergic
response, exacerbating medications or concurrent disease, and unpredictability. The most common causes of anaphylaxis are
food allergies, stinging insects and immunotherapy (allergy shots) but idiopathic anaphylaxis, latex allergy and drug
hypersensitive all contribute to the epidemiology. Reactions to IVPand other dyes are coined anaphylactoid reactions but have
identical pathophysiology and treatment, once the mast cell has been degranulated. As many antigens can be the trigger for
fatal anaphylaxis, it is useful to examine the features of each etiology individually, highlighting factors common to all fatal
anaphylaxis and some speciﬁc to certain etiologies. Generally what distinguishes a fatal from non fatal reaction is often just the
rapidity to apply correct therapy. Prevention is clearly the key and should identify high-risk patients in an attempt to minimize
the likely of a severe reaction. Although fatal anaphylaxis is rare, it is likely underreported.
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Introduction
The term “anaphylaxis” entered the scientiﬁc
literature in 1902, when Richet and Potier described
the hypotensive effects of sea anemone allergens in
dogs (Cohen and Zelaya-Quesada 2002). Today,
anaphylaxis generally refers to a potentially fatal
group of symptoms and signs due to an immediate
hypersensitivity reaction affecting one or multiple
organ systems. Classically, anaphylaxis implies an
immunoglobulin E (IgE)-mediated release of
mediators from mast cells and basophils after antigen
causes cross-linking of the IgE receptors on these
cells. However, there is not a universally accepted
deﬁnition of anaphylaxis, and it is often used to
describe non-IgE-mediated or other non-immunolo-
gic events (sometimes called “anaphylactoid”) as well
(Anthony 2005). Symptoms and signs that may be
present singly, in combination, and in varying degrees
of severity involve the skin (urticaria, angioedema,
ﬂushing, pruritis), the cardiopulmonary system
(hypotension, syncope/presyncope, tachycardia,
arrhythmia, wheezing, stridor, hypoxia, sudden
death), the gastrointestinal system (nausea, vomiting,
diarrhea, abdominal pain) and other systems (uterine
cramps, rhinoconjunctivitis, headache, sense of
impending doom) (Table I). The lessons gleaned
from reviews of cases of fatal anaphylaxis may help
physicians understand why people die and may help
initiate management approaches that prevent ana-
phylaxis. With this in mind, the goal of this discussion
is to highlight some of the signiﬁcant ﬁndings and
lessons learned from studies on fatal anaphylaxis.
Epidemiology
Exact incidence measures for anaphylaxis and fatal
anaphylaxis are unknown, and many studies document
under-reporting of events (Lieberman 2003). This
wouldsuggestthatthedatawehave,underestimatesthe
true incidence of this problem. Numerous authors have
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epidemiology (Kemp and Lockey 2002, Lieberman
2003, Moneret-Vautrin et al. 2005). Despite the
limitations and variability of the data available, some
senseofthescaleoftheproblemisobtainedbylookingat
estimates of incidence of fatal anaphylaxis. An
international epidemiological study estimates that 154
fatal episodes of anaphylaxis occur per 1,00,000
hospitalized patients per year (International collabora-
tive study of severe anaphylaxis 1998). In the United
States,theriskofanaphylaxisperindividualissuggested
to be from less than one, up to 3% (Yocum et al. 1999,
KempandLockey2002),while1500deathsarethought
to occur annually due to anaphylaxis (Neugut et al.
2001). Pumphrey has collected detailed data on
anaphylactic deaths in the United Kingdom (UK)
from 1992–2001. His data suggests that in the UK,
thereareabout20fatalitiesper year,whichcorresponds
to one per year for each 3 million people (Pumphrey
2004). Unfortunately this is likely an underestimate
as many fatalities go unreported in the medical
literature.
Pathology and modes of death
Autopsy data from patientswho died from anaphylaxis
revealthat,inmanycases,therearenospeciﬁcﬁndings
by macroscopic exam (Pumphrey and Roberts 2000).
Most fatal reactions are limited to a single system or
area (such as cardiovascular or respiratory or upper
Table I. Signs and symptoms of anaphylaxis in the various target organs and tissues.
Percentage of patients affected
Affected organ or tissue Speciﬁc signs and symptoms
Yocum et al. adults
(n ¼ 133)
Dibs et al. children 1–19 years of age
(n ¼ 55)
Cutaneous/dermatologic Urticaria 100 93
Angioedema
Pruritus
Flushing
Conjunctivitis or chemosis
Respiratory Upper airway: 69 93
Nasal congestion
Sneezing
Hoarseness
Stridor
Cough
Obstruction
Throat tightness
Laryngeal edema
Lower airway:
Dyspnea
Bronchospasm
Tachypnea
Wheezing
Cyanosis
Respiratory arrest
Oral/gastrointestinal Intraoral 24 13
Angioedema
Emesis
Nausea
Abdominal cramps
Dysphagia
Diarrhea
Cardiovascular Tachycardia 41 26
Presyncope
Hypotension
Shock
Chest pain
Bradycardia
Orthostasis
Cardiac arrest
Neurological Feeling of impending doom Not determined 26
Dizziness
Weakness
Syncope
Seizures
A. Kumar et al. 282airway), not usually the case with less severe
anaphylaxis (Pumphrey 2004). Pumphrey found that
shock occurred from different causes in older versus
younger patients. Younger patients who died of
anaphylactic shock tended to experience vasodilation
withhypotension,leadingtopulselesselectricalactivity
anddeath(Pumphrey2004).Intheolderpatientsinhis
UK register, shock was found to be from arrhythmia,
which is more commonly found in older hearts with
pre-existing disease (Pumphrey 2004). In this series,
respiratory arrest was due to bronchospasm, upper
airway edema, or a combination of the two. Bronch-
ospastic respiratory arrest was more common in food-
induced anaphylaxis, while shock was more likely with
drugs and venom reactions. Respiratory arrest due to
upper airway edema was more common in food and
venom reactions than in drug reactions (Pumphrey
2004). Less common modes of death include
disseminated intravascular coagulation and compli-
cations from epinephrine overdose. One practical
point related to modes of death in fatal anaphylaxis
relates to posture. Pumphrey found that four of the
patients in his register that died of shock died within
seconds of a “change to a more upright posture”
(Pumphrey 2003). It is felt that patients suffering from
anaphylactic shock cannot tolerate the emptying of the
vena cava that results when they are made to sit up or
stand since it will cause loss of left ventricular ﬁlling
pressure, myocardial ischemia, pulseless electrical
activity, and quickly, death (Pumphrey 2003).
The lesson from these facts is that patients with
anaphylaxis should be kept supine if their respiratory
statuswilltoleratethis.Theyshouldalsohavetheirlegs
elevated to increase ﬁlling of the vena cava and heart.
These recommendations should be incorporated
into education for patients and medical staff
(Pumphrey 2003).
Etiology
The most commonly identiﬁed causes of anaphylaxis
are immunotherapy, foods, medications, diagnostic
agents, stinging insect venom and latex (Lieberman
2003). Idiopathic anaphylaxis is also signiﬁcant, since
studies have shown that the etiology of anaphylaxis is
not found in 47% or more of cases presenting to
allergist-immunologists(Kempetal.1995,Lieberman
2003). As any of the above can be the trigger for fatal
anaphylaxis, it is useful to examine the features of each
etiology individually, highlighting factors common to
all fatal anaphylaxis and some speciﬁc to certain
etiologies. Reactions to IVP and other contrast media
are identical to anaphylaxis, once the mast cell has
degranulatedandwillnotbediscussedinfurtherdetail
except to emphasize that what distinguished a fatal
fromnotfatalreactionisoftenjusttherapiditytoapply
correct therapy.
Fatal anaphylaxis by etiology
Food anaphylaxis
Several series, epidemiological studies, and literature
reviews report food as the most common cause of
anaphylaxis (Yocum and Khan 1994, Kemp et al.
1995, Yocum et al. 1999, Lieberman 2003). It is
estimated that foods cause fatal anaphylaxis in 125–
150 Americans annually (Burks et al. 1999, Bock et al.
2001). Pumphrey found that about 6 of 19
anaphylactic fatalities per year that occur in the UK
are due to foods (Pumphrey). Peanuts and tree nuts
are the predominant offenders, accounting for 94% of
32 fatal cases reported to a national registry and
making up the majority of food anaphylaxis deaths in
Pumphrey’s UK register of fatal anaphylaxis (Bock
et al. 2001). However, all foods (Moneret-Vautrin
et al. 2005) and allergens have the potential to cause
fatal anaphylaxis. Fatalities found in the UK register
also include 14% due to cow’s milk, and smaller
numbers from ﬁsh, shellﬁsh, chickpea, hen’s egg, and
banana (Pumphrey 2004). Bock et al. (2001) found
that food-related fatal anaphylaxis affects both sexes
equally, while the UK register described a female
predominance (Pumphrey 2004). The majority of
victims are young (adolescents to young adults)
(Sampson et al. 1992, Wuthrich 2000, Bock et al.
2001, Pumphrey 2004). All but one of the 32 patients
in Bock’s study and all of the patients with food as the
etiology in the UK register had a history of a prior
reaction to foods before the fatal event (Pumphrey and
Nicholls 2000, Bock et al. 2001). Of even more
signiﬁcance is the fact that 80% of the UK registry
patientswho died of food-related anaphylaxis had only
minor previous reactions, suggesting that severity of
prior reaction cannot be used to identify who is at risk
of fatal reactions, or even to guide prescription of
epinephrine self-treatment (Pumphrey 2004). Asthma
seems to play an important role in fatal food
anaphylaxis and may make reversing bronchospasm
from anaphylaxis more difﬁcult (Sampson et al.
1992). All but one in Bock’s study had asthma
(Bock et al. 2001), and all of the those with food as a
cause in the UK register had difﬁculty breathing, with
86% of these proceeding to respiratory arrest
(Pumphrey 2003). Most of the UK register patients
who died due to foods also had suboptimally
controlled asthma, many using daily beta-agonist
therapy and not regularly using inhaled corticosteroids
(Pumphrey 2004). Frequent beta-agonist use may
result in resistance to epinephrine, making treatment
of anaphylaxis more difﬁcult (Pumphrey and Nicholls
2000). The predominance of pulmonary symptoms in
these cases caused some paramedics to be uncertain
about initiating an anaphylaxis treatment protocol or
one for asthma, which led to treatment delays or
inappropriate treatments, both of which may have
contributed to the fatal outcomes (Pumphrey and
Anaphylaxis 283Nicholls 2000). Based on these data, Pumphrey and
Nicholls (2000) argues that we may decrease food
anaphylaxis fatalities by emphasizing use of inhaled
beta-agonists (as a supplement to epinephrine) as part
of the acute anaphylaxis self-treatment plan. In
fatalities due to foods, although the median time to
respiratory or cardiac arrest was 30min in the UK
register, some food reactions started with very mild
symptoms and progressed over several hours to a ﬁnal
rapid arrest (Pumphrey and Nicholls 2000). Such
initially mild symptoms may lead to less aggressive
management that allows progression of ultimately
fatal reactions. Another problem that contributes to
fatal results in food-related anaphylaxis is delayed or
absent treatment with epinephrine. Ninety percent of
those in Bock’s study did not have epinephrine auto-
injectors (EAIs) (Bock et al. 2001). Other studies have
also found that many patients who have a prescribed
EAI do not carry or do not use the device in situations
where EAI use was thought to be appropriate by the
physician (Pumphrey and Nicholls 2000). In some
instances, EAIs are not used due to lack of
appropriate training (Huang 1998). In others, the
device is expired (Pumphrey and Nicholls 2000). In
many cases of food-anaphylaxis fatalities in the UK
registry, there was a delay in epinephrine treatment,
with many not receiving this treatment until after
cardiopulmonary arrest (Pumphrey and Nicholls
2000). This was due to the rapid evolution of the
reaction in some and the availability of treatment in
others. Although, early use of epinephrine in
anaphylaxis is supported by national management
guidelines (Anthony 2005) and experts in the ﬁeld
(Bock et al. 2001), sometimes fatalities occur despite
appropriately timed and dosed use of epinephrine.
This was seen in both the UK registry and the group
studied by Bock et al. (2001) (Pumphrey and
Nicholls 2000). This data makes education of
patients regarding allergen avoidance, food labels,
cross-contamination, and early recognition of the
symptoms and signs of anaphylaxis all the more
important.
Given the high incidence of cross-contamination
with nuts, particularly when eating in restaurants,
some suggest that any patient allergic to one nut
should be evaluated for allergy to other nuts and be
advised to avoid all nuts (Pumphrey and Nicholls
2000). Other issues that make fatal reactions to food
more likely include the minute quantities (Hourihane
et al. 1997) of allergen sometimes required to cause
anaphylaxis and the resultant difﬁculties in completely
avoiding these allergens. Despite education of parents
and patients, unintentional exposures to food aller-
gens, particularly nuts, occur and may cause recurrent
reactions (Sicherer et al. 1998). This fact again
emphasizes the need for education of patients and
physicians regarding action plans for food anaphylaxis
and early recognition of symptoms.
Drug/diagnostic agent/iatrogenic anaphylaxis
Iatrogenic causes of anaphylaxis are common. Drugs
are felt to be second only to foods as a cause for
anaphylaxis (Lieberman 2003), and hundreds of these
agents have been known to cause anaphylaxis (Neugut
et al. 2001). These reactions affect older patients than
due foods (Pumphrey). Again, incidence data is
variable by study, 50 deaths annually in the Nether-
lands(vanderKlauwetal.1996)peryear,30casesover
a 22-year period in Denmark (Lenler-Petersen et al.
1995), and 9 per year (50% of total deaths) in the UK
registry (Pumphrey). Antibiotics, particularly beta-
lactams, are felt to be the most frequent offenders with
NSAIDS also causing signiﬁcant numbers of anaphy-
laxisepisodes(Lieberman2003).Radiocontrastmedia
is a common fatal trigger, causing an estimated 900
deaths annually in the United States (Neugut et al.
2001). Lower-osmolarity, non-ionic agents appear to
be safer (Katayama et al. 1990). Risk of reaction in
patients on beta-blockers is higher (Toogood 1988).
Duringanesthesia,commoncausesoffatalanaphylaxis
include muscle relaxants, which may have a synergistic
response with opioids to make reactions more severe
(Pumphrey 2004). Allergen immunotherapy has been
found to cause fatal reactions in 1 per every 2.5 million
shotsgiven,andcauses3.4deathsannually.Thedeaths
are primarily in asthmatics with sub-optimal control of
asthma, during maintenance dosing of immunother-
apy, in settings without adequate mechanisms of
anaphylaxis treatment, and associated with delayed
administration of epinephrine, but not typically due to
dosing errors (Bernstein et al. 2004). The same study
reported one death from allergen skin testing to 90
different food allergens performed on a patient with
poorly controlled asthma. Although, latex allergy has
increased over the last decade, latex-induced fatal
anaphylaxis seems to be rare (Pumphrey 2004,
Bernstein et al. 2004, Moneret-Vautrin et al. 2005).
Drugs usually cause cardiac arrest with shock rather
than asphyxia from bronchospasm or laryngeal/phar-
yngealedema,whichisseenmorecommonlywithfood
cases (Pumphrey and Nicholls 2000). Also, deaths
from drug-induced anaphylaxis tend to be character-
ized by a much more rapid (within minutes) onset and
progression to arrest (Pumphrey and Nicholls 2000).
Such rapid progression of symptoms can make
treatment more difﬁcult and error-prone. Pumphrey
and others have documented that epinephrine,
arguably the most important drug in anaphylaxis
management, is sometimes given at inappropriately
high doses intravenously during anaphylaxis (Pum-
phrey and Nicholls 2000). This has caused fatal
pulmonary edema and myocardial infarction. Clearly,
further education of physicians and nurses regarding
giving only dilute epinephrine doses intravenously is
warranted. Other efforts that may prevent these errors
include regular anaphylaxis drills in clinic and hospital
A. Kumar et al. 284settings. The fact that these deaths often occur despite
aggressiveandrapidtreatmentforhospitalizedpatients
makes it clear that some reactions are so severe that
death is not preventable. In such cases, measures to
avoidagentsthatmayhavecross-reactivepotentialmay
be at least as important as rescue efforts (Pumphrey
and Nicholls 2000).
Stinging insect venom anaphylaxis
Venom reactions comprise 11–58% of anaphylaxis
triggers, dependent on which study is cited (Moneret-
Vautrin et al. 2005). An estimated 40–100 Ameri-
cans die annually due to envenomation and
subsequent anaphylaxis from stinging insects of the
order hymenoptera (Neugut et al. 2001). One quarter
of the 20 patients that die from anaphylaxis in the UK
annually die from insect venom reactions (Toogood
1988). The patients in the UK registry who died from
venom reactions had a peak age of 45–70, tended to
be male, and were often atopic (Pumphrey 2004).
Time to arrest in this group was 10–15min,
intermediate relative to food and drug cases. These
patients also tended to die due to shock, similar to
drug cases and unlike the deaths related to foods.
Another disturbing feature of the group is that more
than two-thirds of these venom deaths occurred in
patients who had never had a generalized reaction to
venom in the past, and thus were not even candidates
for carrying EAI or for consideration of venom
immunotherapy. Additionally, some venom deaths
occur in patients who have not received immunother-
apy, but who should have received it according to
current guidelines (Pumphrey 2004). This makes it
clear that at minimum, we should be offering this
generally very effective form of therapy to patients
who meet desensitization criteria and lack deﬁnite
contraindications to treatment. Some (Sasvary and
Muller 1994) have found a higher incidence of
coronary artery disease in those that die from venom
reactions, but others (Pumphrey 2004) have not. The
fact that some deaths (Light 2001) have occurred in
patients despite venom immunotherapy, emphasizes
the need for effective education of patients regarding
avoidance, regular carrying of EAIs, and proper EAI
use. Another feature of venom deaths is its
relationship to mastocytosis. The UK register
documented one case (Pumphrey 2004), and it is
known that patients with mastocytosis have an
elevation of tryptase at baseline that may lead to
more severe reactions to venom (Ludolph-Hauser
et al. 2001, Haeberli et al. 2003).
Immunotherapy
Even though the risk of fatal reactions to immu-
notherapy is low, any death is unacceptable. Further
deaths from immunotherapy are nearly always the
result of error. Therefore, many investigators have
looked for commonalities between fatal cases in an
attempt to identify speciﬁc risk factors. Since most
deaths after immunotherapy are attributable to fatal
anaphylaxis, the most severe form of a systemic
allergic reaction (SR), great efforts have also been
made to identify risk factors for SRs in general and for
severe, but non-fatal, SRs in particular. Unfortu-
nately, widely differing deﬁnitions of SR have been
used and this is reﬂected in the great variation in the
reported rates of SRs, which range from ,1 to 100%
of patients. Factors like differences in patient
characteristics, types of allergens, and administration
protocols are also likely to contribute to the variability
of the results. Some of these risk factors include the
presence of asthma; multiple studies have reported a
higher proportion of asthma patients among the
deaths associated with immunotherapy (Medicines
CoS 1986, Lockey et al. 1987, Reid et al. 1993,
Kordash and Miller 1997). In addition, many fatal
reactions to immunotherapy occur when the doses are
increased, as opposed to maintenance. However, it
should be emphasized that maintenance dose should
not contain an excessive dose of allergen (Medicines
CoS 1986, Tabar et al. 1993, Nettis et al. 2002). It has
also been noted that anaphylaxis to pollen allergens is
likely to occur during allergy season when patients are
also exposed to aeroallergen. It is also noted that
patients with high levels of IgE, as noted by the skin
test or RAST, are also more commonly affected by
fatal reactions (Lin et al. 1993, Bousquet et al. 1998).
Although at least one paper has suggested that local
reactions may not be predictive of fatal reactions, it
should be emphasized that multiple other obser-
vations have suggested that local reactions are a major
risk factor and while not 100% predictive,are a serious
warning that allergen immunotherapy dosage should
be reduced. Fatal reactions have also been reported in
patients who had previously undergone serious
Table II. Sources of potential treatment errors in immunotherapy
(IT).
1. Errors in dosage, including failure to reduce the dosage after
a longer than scheduled interval between injections or
after an adverse reaction to a previous injection or when
injecting extract from a new vial, particularly one from
a different manufacturer.
2. Failure to provide the patients with all the appropriate
information.
3. Failure to observe the patient for the appropriate length of
time after the injection.
4. Mixture of seasonal and perennial allergens.
5. Failure to adhere to established guidelines for contraindications
to IT.
6. Failureto postponetheinjection becauseof an existing infection
or asthma exacerbation.
7. Inadvertent intravenous administration.
8. Administration of the wrong extract.
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whom a new vial of allergen has been opened, and in
patients receiving beta-blocking agents (Lockey et al.
1987, Malling and Weeke 1993, Reid et al. 1993,
Bousquet et al. 1998). We should note that recent
studies suggest that beta-blockers, particularly the
more selective agents, may not pose a signiﬁcant risk
(Hepner et al. 1990). Fatal reactions also occur from
treatment errors (Table II). Immunotherapy should
never be undertaken unless physicians are aware of
and aggressive in the correct treatment of
anaphylaxis.
Idiopathic anaphylaxis
As discussed previously, no cause is found in many
cases of anaphylaxis. Idiopathic anaphylaxis is
deﬁned as anaphylaxis for which no identiﬁable
cause is found. Unidentiﬁed food allergens are
thought to be the trigger in some of these cases
(Pumphrey 2004). Despite the frequency of this
diagnosis, fatalities due to the syndrome of idiopathic
anaphylaxis are uncommon. One series of 350
patients had one fatality (Krasnick et al. 1996),
though others also have reported some cases
(Patterson et al. 1995).
Final comments
Anaphylaxis is a source of anxiety for patients and
healthcare providers. It is a medical emergency that
presents with a broad array of symptoms and signs,
many of which can be deceptively similar to other
diseases such as myocardial infarction, asthma, or
panic attacks. In addition to these diagnostic
challenges, anaphylaxis presents management difﬁ-
culties due to rapid onset and progression, lack of
appropriate self-treatment education and implemen-
tation by patients, severity of the allergic response,
exacerbating medications or concurrent disease, and
unpredictability. Large randomized clinical trials
regarding the best management are unlikely to be
performed given the rarity of anaphylaxis and ethical
issues regarding withholding speciﬁc treatments in
these potentially fatal situations. It is likely that many
of us as physicians will face severe or even fatal
anaphylaxis in patients due to foods, drugs, or venom.
Clearly there is no way to eliminate fatal reactions in
all cases, but attention to some of the lessons learned
Table III. Treatment of anaphylaxis.
1. Symptoms not immediately life-threatening may rapidly progress unless treated promptly
(a) Intramuscular or subcutaneous epinephrine (intramuscular preferred)
(i) Adults-0.2ml (0.2mg)–0.5ml (0.5mg) of a 1:1000 w/v (1mg/ml) dilution every 10–15min, up to a maximum of 1ml
(1mg) per dose
(ii) Children-0.01ml (0.01mg)/kg body weight up to a maximum of 0.5ml (0.5mg) per dose of 1:1000 (1mg/ml) w/v dilution,
repeated every 15min for 2 doses, then every 4h as needed
(b) Diphenhydramine: 1–2mg/kg or 25–50mg per dose may be given parenterally.
(c) Intravenous Corticosteroids (hydrocortisone (e.g. Solucortef)): Recommended, but efﬁcacy not clearly delineated.
2. Immediate treatment of life-threatening anaphylaxis includes:
(a) Intramuscular or subcutaneous epinephrine at dosage described above
(b) Intravenous epinephrine can be considered if the patient signiﬁcantly worsens despite repeated doses of subcutaneous or
intramuscular epinephrine; administered either by using a formulation of 1:10,000 (0.1mg/ml) or 1:1,00,000 (0.01mg/ml) w/v
dilution initially titrated at 1mg/min which can be increased to 2–10mg/min as needed
(c) CPR as needed to restore circulation and respiration
(d) Vasopressors and intravenous ﬂuids to treat hypotension
(e) Oxygen
(f) Inhaled b-adrenergic bronchodilator for bronchospasm
(g) Constant monitoring of cardiac, respiratory and circulatory systems.
3. A good clinical response indicates resolution of the anaphylactic reaction. Continued monitoring is indicated if (1) the response appears
incomplete, or (2) biphasic anaphylaxis appears likely. Additional history and laboratory tests will add to the diagnostic base. Consider
antihistamines for urticaria/angioedema, and H2-receptor blocking drugs for epinephrine-resistant hypotension.
4. Additional treatment may be required for patients who:
(1) are unresponsive to epinephrine due to b-adrenergic blocking therapy (consider ﬂuid replacement, epinephrine, and if still
unresponsive consider glucagon 1mg intravenously as a bolus with continuous infusion of 1–5mg/h)
(2) for prominent respiratory symptoms (consider inhaled b-adrenergic agonist)
(3) need hospital admission for extended management or management of comorbid conditions.
5. Monitor for late-phase reactions
(1) in a medical setting for an extended period, for life-threatening episodes, or
(2) at home if the reaction was mild.
6. Follow-up includes complete evaluation and a long-term treatment plan in consultation with an allergist/immunologist.
The diagnosis and management of anaphylaxis. J Allergy Clin Immunol 1998;101:S465–S528.
A. Kumar et al. 286from prior deaths may decrease the frequency of these
tragic episodes (Table III).
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